Given the importance of CD8+ T cells and tumor-specific MHC-I in the tumor control mediated by Pikfyve depletion, we speculated that PIKfyve inhibition could augment immunotherapies that were CD8+ T cell- and MHC class I-dependent. Here, PIKFYVE is linked to neoplasm.